ImmuPharma (LON:IMM) Trading 34.1% Higher - Here's What Happened

Key Points

• ImmuPharma's shares increased by 34.1% during mid-day trading, climbing from a previous close of GBX 8.06 to a high of GBX 11.50.
• The trading volume surged to 57,593,953 shares, reflecting a 656% increase compared to the average session volume.
• ImmuPharma, specializing in peptide-based therapeutics for autoimmune diseases, has a net margin of 3,519.56% but is projected to report a significantly negative EPS for the current year.

ImmuPharma plc (LON:IMM - Get Free Report) traded up 34.1% on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). 57,593,953 shares traded hands during mid-day trading, an increase of 656% from the average session volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Price Performance

The company has a 50-day simple moving average of GBX 3.12 and a two-hundred day simple moving average of GBX 2.92. The stock has a market capitalization of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.